January 11, 2016
FLOW-i can help save up to 32% on anesthetic agent

In a retrospective six-month cost comparison of volatile agent usage of anesthesia delivery technologies, anesthetic agent consumption with FLOW-i was significantly lower than competitive anesthesia machines, making it a cost-effective option for optimal patient care in the Hybrid OR.

In the study, FLOW-i was estimated to result in a 32% cost savings in volatile agent consumption.1  How does this translate into hospital savings over the course of a year? View the details here.

For more information about FLOW-i or other Hybrid OR components, please contact Maquet at hybridinfo@getinge.com..
Reference:   1. Observational Study: Anesthesia agent consumption experience of volatile agent cost savings with new anesthesia delivery technology in longer surgical procedures, Dr. Suzanne Thomson, Glasgow, United Kingdom. Document on file Maquet MCV00029362.

Make the Hybrid OR process easier with the right partnership.

The ideal Hybrid OR features a multidisciplinary space that supports both interventional and surgical…

Read More

CARDIOSAVE: A first-line therapy for hemodynamic support.

It makes sense to have the most widely used mechanical circulatory support device available as a go-to…

Read More

FLOW-i can help save up to 32% on anesthetic agent

In a retrospective six-month cost comparison of volatile agent usage of anesthesia delivery technologies,…

Read More

FLOW-i makes responsive support easy in the Hybrid OR.

The most effective Hybrid ORs involve many components and disciplines working in collaboration to achieve…

Read More
View All
Live chat by BoldChat